filmov
tv
Navigating ER+ metastatic breast cancer: Explore a patient case
Показать описание
In this on-demand Tweetorial video from BREAST CANCER CONNECT, Dr Paolo Tarantino presents a patient with ER+/HER2- de novo metastatic breast cancer, exploring the entire diagnostic and treatment process.
Dr Tarantino discusses:
• Guidelines recommend performing molecular testing with ctDNA to tailor treatment strategies in cases of recurrence or progression on endocrine therapy
• Elacestrant, as the first FDA-approved oral SERD (January 2023), offers a promising choice for select patients with ER+/HER2- metastatic breast cancer harbouring an ESR1 mutation
• Oral SERDs are being studied as a monotherapy and in combination with targeted therapies (i.e. CDK4/6, PI3K and AKT inhibitors), offering promising prospects for their integration into clinical practice
Nov 2023
Dr Tarantino discusses:
• Guidelines recommend performing molecular testing with ctDNA to tailor treatment strategies in cases of recurrence or progression on endocrine therapy
• Elacestrant, as the first FDA-approved oral SERD (January 2023), offers a promising choice for select patients with ER+/HER2- metastatic breast cancer harbouring an ESR1 mutation
• Oral SERDs are being studied as a monotherapy and in combination with targeted therapies (i.e. CDK4/6, PI3K and AKT inhibitors), offering promising prospects for their integration into clinical practice
Nov 2023
0:54:02
0:57:18
0:44:23
1:06:20
0:01:37
0:54:51
0:55:33
1:52:27
0:59:38
0:14:24
0:02:10
0:59:56
0:03:13
0:01:53
0:50:22
0:13:00
1:40:05
0:52:22
0:11:22
1:02:55
0:53:02
0:02:27
0:02:15